1248 Management’s Regeneron Pharmaceuticals REGN Stock Holding History

1248 Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$705K	Hold	913	–	–	0.33%	43
2025 Q4	$705K	Buy	+913	New	+$620K	0.38%	42

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

1248 Management's REGN Position: Q1 2026 in Review

1248 Management held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 913 shares worth $705K. The position accounts for 0.33% of the portfolio, ranked #43.

1248 Management first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

1248 Management held 913 shares of Regeneron Pharmaceuticals worth $705K as of Q1 2026.
1248 Management left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.33% of 1248 Management's portfolio in Q1 2026, its #43 holding.
1248 Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on 1248 Management's 13F filing for Q1 2026, filed 15 May 2026.